| Year |
Citation |
Score |
| 2023 |
Dy GK, Govindan R, Velcheti V, Falchook GS, Italiano A, Wolf J, Sacher AG, Takahashi T, Ramalingam SS, Dooms C, Kim DW, Addeo A, Desai J, Schuler M, Tomasini P, ... Hong DS, et al. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2202524. PMID 37098232 DOI: 10.1200/JCO.22.02524 |
0.302 |
|
| 2023 |
Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, et al. Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. Npj Precision Oncology. 7: 37. PMID 37072571 DOI: 10.1038/s41698-023-00369-w |
0.322 |
|
| 2022 |
Raghav KP, Stephen B, Karp DD, Piha-Paul SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF, Overman M, Smaglo B, Huey RW, Meric-Bernstam F, Varadhachary GR, Naing A. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. Journal For Immunotherapy of Cancer. 10. PMID 35618285 DOI: 10.1136/jitc-2022-004822 |
0.308 |
|
| 2022 |
Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, et al. Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Scientific Reports. 12: 8701. PMID 35610322 DOI: 10.1038/s41598-022-12669-5 |
0.314 |
|
| 2021 |
Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Fu S, Subbiah V, Hong DS, Yap TA, Shah J, Milton DR, McQuinn L, Gong J, Tran Y, Carter BW, et al. Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors. Experimental Hematology & Oncology. 10: 59. PMID 34965890 DOI: 10.1186/s40164-021-00251-0 |
0.325 |
|
| 2021 |
Kato S, Adashek JJ, Subbiah V, Fu S, Sun M, Nguyen L, Brown EJ, Yap TA, Karp DD, Piha-Paul SA, Hong DS. A phase i study of ixazomib and erlotinib in patients with advanced solid tumors. Investigational New Drugs. PMID 34468905 DOI: 10.1007/s10637-021-01153-y |
0.323 |
|
| 2021 |
Tsimberidou AM, Hong DS, Fu S, Karp DD, Piha-Paul S, Kies MS, Ravi V, Subbiah V, Patel SM, Tu SM, Janku F, Heymach J, Johnson A, Cartwright C, Zhao L, et al. Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. Npj Precision Oncology. 5: 21. PMID 33742104 DOI: 10.1038/s41698-021-00159-2 |
0.306 |
|
| 2021 |
Hong DS, Strickler JH, Fakih M, Falchook GS, Li BT, Durm GA, Burns TF, Ramalingam SS, Goldberg SB, Frank RC, Marrone K, Shu CA, Gandara DR, Soman N, Henary HA, et al. Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101). Journal of Clinical Oncology. 39: TPS2669-TPS2669. DOI: 10.1200/JCO.2021.39.15_SUPPL.TPS2669 |
0.309 |
|
| 2021 |
Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul SAA, Subbiah V, Janku F, Naing A, Yap TA, Rodon Ahnert J, Ajani JA, Cartwright C, Naqvi MF, Nogueras-Gonzalez GM, Miller VA, et al. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT2): Challenges and Opportunities in Conducting an MD Anderson Randomized Study in Precision Oncology. Journal of Clinical Oncology. 39: 3140-3140. DOI: 10.1200/JCO.2021.39.15_SUPPL.3140 |
0.338 |
|
| 2020 |
Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, et al. Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes. Molecular Cancer Research : McR. PMID 33323389 DOI: 10.1158/1541-7786.MCR-20-0751 |
0.332 |
|
| 2020 |
Wang Y, Janku F, Piha-Paul S, Hess K, Broaddus R, Liu L, Shi N, Overman M, Kopetz S, Subbiah V, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, et al. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Scientific Reports. 10: 3080. PMID 32080210 DOI: 10.1038/S41598-020-58366-Z |
0.314 |
|
| 2020 |
Berlin J, Hong DS, Deeken JF, Boni V, Oh D, Patel JD, Nanda S, Brega N, Childs BH, Hyman DM, Drilon AE. Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. Journal of Clinical Oncology. 38: 824-824. DOI: 10.1200/jco.2020.38.4_suppl.824 |
0.328 |
|
| 2020 |
Fakih M, Durm GA, Govindan R, Falchook GS, Soman N, Henary HA, Hong DS. Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101). Journal of Clinical Oncology. 38: TPS3661-TPS3661. DOI: 10.1200/jco.2020.38.15_suppl.tps3661 |
0.329 |
|
| 2020 |
Drilon AE, Farago AF, Tan DS, Kummar S, McDermott RS, Berlin J, Patel JD, Brose MS, Leyvraz S, Tahara M, Solomon BM, Reeves JA, Fellous MM, Brega N, Childs BH, ... ... Hong DS, et al. Activity and safety of larotrectinib in adult patients with TRK fusion cancer: An expanded data set. Journal of Clinical Oncology. 38: 3610-3610. DOI: 10.1200/jco.2020.38.15_suppl.3610 |
0.306 |
|
| 2019 |
Sullivan RJ, Hollebecque A, Flaherty KT, Shapiro GI, Rodon Ahnert J, Millward MJ, Zhang W, Gao L, Sykes A, Willard MD, Yu D, Schade AE, Crowe KJ, Flynn DL, Kaufman MD, ... ... Hong DS, et al. A Phase 1 Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. Molecular Cancer Therapeutics. PMID 31645440 DOI: 10.1158/1535-7163.Mct-19-0681 |
0.301 |
|
| 2019 |
Hong DS, Tehrani OS, Safran H, Steuer CE, Lacy J, Taylor MH, George TJ, Rangwala RA, Jain S, Viana Nicacio L, Cho MT. SGNTV-001: Open label phase 2 study of tisotumab vedotin for locally advanced or metastatic disease in solid tumors. Journal of Clinical Oncology. 37: TPS3160-TPS3160. DOI: 10.1200/JCO.2019.37.15_SUPPL.TPS3160 |
0.311 |
|
| 2019 |
Sen S, Hess KR, Hong DS, Falchook GS, Pestana R, Janku F, Naing A, Benjamin RS, Patel S, Meric-Bernstam F, Subbiah V. Survival and signals of response in advanced sarcoma patients enrolled on phase 1 trials in the era of precision oncology and novel immunotherapies. Journal of Clinical Oncology. 37: 11063-11063. DOI: 10.1200/JCO.2019.37.15_SUPPL.11063 |
0.308 |
|
| 2019 |
Kurnit KC, Meric-Bernstam F, Hess K, Coleman RL, Bhosale P, Savelieva K, Janku F, Hong D, Naing A, Pant S, Rodon J, Yap TA, Sood AK, Soliman PT, Gershenson DM, et al. Abstract CT020: Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct020 |
0.325 |
|
| 2019 |
Hegde A, Huang L, Liu S, Hess K, Cabanillas M, Hu M, Busaidy N, Sherman S, Simon G, Blumenschein G, Papadimitrakopoulou VA, Hong DS, Meric-Bernstam F, Heymach J, Subbiah V. Abstract 4997: Responsiveness to immune checkpoint inhibitors in RET dependent cancers Cancer Research. 79: 4997-4997. DOI: 10.1158/1538-7445.Am2019-4997 |
0.316 |
|
| 2018 |
Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget. 9: 33232-33243. PMID 30237864 DOI: 10.18632/Oncotarget.26075 |
0.316 |
|
| 2018 |
Patnaik A, Gordon M, Tsai F, Papadopoulous K, Rasco D, Beeram SM, Fu S, Janku F, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB, Hong D. A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer Chemotherapy and Pharmacology. PMID 29926131 DOI: 10.1007/s00280-018-3623-7 |
0.309 |
|
| 2017 |
Varadhachary GR, Raghav KPS, Pant S, Janku F, Fu S, Hong DS, Piha-Paul SA, Colen RR, Subbiah V, Painter J, Tsimberidou AM, Stephen B, Karp DD, McQuinn L, Mendoza TR, et al. Phase II study for the evaluation of efficacy of pembrolizumab (MK-3475) in patients with cancer of unknown primary. Journal of Clinical Oncology. 35: TPS3103-TPS3103. DOI: 10.1200/JCO.2017.35.15_SUPPL.TPS3103 |
0.319 |
|
| 2017 |
Naing A, Lopez-Berestein G, Fu S, Tsimberidou AM, Pant S, Piha-Paul SA, Janku F, Hong DS, Sulovic S, Meng X, Jazaeri AA, Ng CS, Karp DD, Subbiah V, Meric-Bernstam F, et al. EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A phase I clinical trial. Journal of Clinical Oncology. 35: TPS2604-TPS2604. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps2604 |
0.319 |
|
| 2017 |
Naing A, Fu S, Tsimberidou AM, Pant S, Piha-Paul SA, Janku F, Hong DS, Colen RR, Carter BW, Evans E, Tawbi HA, Karp DD, Subbiah V, Dev R, Hess KR, et al. Phase IB study to evaluate the safety of selinexor in combination with multiple standard chemotherapy agents in patients with advanced malignancies. Journal of Clinical Oncology. 35: TPS2603-TPS2603. DOI: 10.1200/JCO.2017.35.15_SUPPL.TPS2603 |
0.334 |
|
| 2017 |
Groisberg R, Hong DS, Janku F, Tsimberidou AM, Javle MM, Meric-Bernstam F, Subbiah V. Clinical next generation sequencing for precision oncology in rare cancers. Journal of Clinical Oncology. 35: 2582-2582. DOI: 10.1200/JCO.2017.35.15_SUPPL.2582 |
0.301 |
|
| 2017 |
Hong DS, Hollebecque A, Gordon MS, Flaherty KT, Shapiro G, Rodon J, Millward M, Ramdas N, Zhang W, Gao L, Sykes A, Willard MD, Yu D, Schade A, Flynn DL, et al. A first-in-human dose phase 1 study of LY3009120 in advanced cancer patients. Journal of Clinical Oncology. 35: 2507-2507. DOI: 10.1200/Jco.2017.35.15_Suppl.2507 |
0.303 |
|
| 2017 |
Tolcher A, Hong D, Sullivan R, Mier J, Shapiro G, Chmielowski B, Ribas A, Postow M, Pearlberg J, Brail L, Lee L, Ullmann CAD, Wolchok JD. Abstract CT089: IPI-549-01 - A Phase 1/1b, first-in-human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct089 |
0.318 |
|
| 2016 |
Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou A, Fogelman D, Bellido J, Shureiqi I, Huang H, et al. Phase 1B Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation. Cancer Discovery. PMID 27729313 DOI: 10.1158/2159-8290.CD-16-0050 |
0.332 |
|
| 2016 |
Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM. Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD Anderson Cancer Center. International Journal of Cancer. PMID 27599876 DOI: 10.1002/Ijc.30417 |
0.315 |
|
| 2016 |
Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, et al. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. PMID 27147567 DOI: 10.18632/Oncotarget.9048 |
0.33 |
|
| 2016 |
Said R, Kakadiaris E, Piha-Paul S, Fu S, Falchook G, Janku F, Wheler JJ, Zinner R, Hong DS, Kurzrock R, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. PMID 27085994 DOI: 10.1007/S00280-016-3000-3 |
0.33 |
|
| 2016 |
Khawaja MR, Nick AM, Madhusudanannair V, Fu S, Hong D, McQuinn LM, Ng CS, Piha-Paul SA, Janku F, Subbiah V, Tsimberidou A, Karp D, Meric-Bernstam F, Lu KH, Naing A. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemotherapy and Pharmacology. PMID 27014780 DOI: 10.1007/s00280-016-3009-7 |
0.309 |
|
| 2016 |
Said R, Ye Y, Hong DS, Naing A, Falchook G, Fu S, Wheler JJ, Piha-Paul S, Tsimberidou AM. Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. PMID 26825327 DOI: 10.1007/s00280-015-2952-z |
0.309 |
|
| 2015 |
Goldstein JB, Tang C, Hong DS, Subbiah V, Janku F, Hess KR, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler JJ, Zinner R, Javle MM, Varadhachary GR, Wolff RA, et al. Evolution of phase 1 trials for patients with advanced pancreatic cancer: An update on the experience from MD Anderson Cancer Center. Journal of Clinical Oncology. 33: 320-320. DOI: 10.1200/jco.2015.33.3_suppl.320 |
0.318 |
|
| 2014 |
Tang C, Jardim DLF, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Galgiato DDM, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. MET nucleotide variations and amplification in advanced ovarian cancer: Characteristics and outcomes with c-Met inhibitors Oncoscience. 1: 5-13. DOI: 10.18632/oncoscience.3 |
0.303 |
|
| 2014 |
Subbiah V, Corrales-Medina FF, Herzog CE, Hess KR, Egas Bejar DE, Hong DS, Falchook GS, Anderson PM, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler JJ, Piha-Paul SA, Janku F, et al. Outcomes of pediatric cancer patients enrolled in phase 1 clinical trials designed for adults: Experience from a major cancer center. Journal of Clinical Oncology. 32: e21024-e21024. DOI: 10.1200/Jco.2014.32.15_Suppl.E21024 |
0.304 |
|
| 2014 |
Tang C, Jardim D, Gagliato D, Falchook G, Hess K, Fu S, Wheler J, Zinner R, Naing A, Tsimberidou A, Meric-Bernstam F, Hong D. Abstract 4424: Analysis of 1115 patients tested for MET amplification and therapy response in the MD Anderson phase I clinic Cancer Research. 74: 4424-4424. DOI: 10.1158/1538-7445.Am2014-4424 |
0.312 |
|
| 2014 |
Janku F, Huang H, Claes B, Falchook G, Naing A, Piha-Paul S, Tsimberidou A, Zinner R, Karp D, Fu S, Subbiah V, Hong D, Wheler J, Luthra R, Patel S, et al. 169 BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform (Idylla™) European Journal of Cancer. 50: 56-57. DOI: 10.1016/S0959-8049(14)70295-3 |
0.318 |
|
| 2013 |
Wheler J, Hong D, Swisher SG, Falchook G, Tsimberidou AM, Helgason T, Naing A, Stephen B, Janku F, Stephens PJ, Yelensky R, Kurzrock R. Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget. 4: 890-8. PMID 23765114 DOI: 10.18632/Oncotarget.1015 |
0.337 |
|
| 2013 |
Jain RK, Lee JJ, Hong D, Kurzrock R. RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. Journal of the National Cancer Institute. 105: 833. PMID 23628598 DOI: 10.1093/Jnci/Djt100 |
0.3 |
|
| 2013 |
Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 4: 156-65. PMID 23391555 DOI: 10.18632/Oncotarget.832 |
0.312 |
|
| 2012 |
Janku F, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Fu S, Piha-Paul SA, Luthra R, Hong DS, Kurzrock R. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 459. PMID 27983190 DOI: 10.1200/Jco.2012.30.4_Suppl.459 |
0.316 |
|
| 2012 |
Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4173-82. PMID 22693357 DOI: 10.1158/1078-0432.Ccr-12-0714 |
0.314 |
|
| 2012 |
Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer. 118: 1422-8. PMID 21823111 DOI: 10.1002/Cncr.26413 |
0.301 |
|
| 2012 |
Subbiah IM, Tsimberidou AM, Naing A, Subbiah V, Kaseb AO, Falchook GS, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Janku F, Kurzrock R. Abstract 2669: Early-phase trials in patients with advanced gallbladder cancer and cholangiocarcinoma: The MD Anderson Clinical Center for Targeted Therapy experience Cancer Research. 72: 2669-2669. DOI: 10.1158/1538-7445.Am2012-2669 |
0.315 |
|
| 2010 |
Kurzrock R, Cohen EE, Sherman SI, Pfister DG, Cohen RB, Ball D, Hong DS, Ng CS, Salgia R, Ratain MJ. Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. Journal of Clinical Oncology. 28: 5502-5502. DOI: 10.1200/Jco.2010.28.15_Suppl.5502 |
0.303 |
|
| 2010 |
Garrido-Laguna I, Bustinza-Linares E, El-Osta H, Janku F, Patel J, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Kurzrock R. Abstract 2773: Clinical outcomes of patients with head and neck tumors enrolled in phase I trials is not inferior to outcomes with last treatment line based on an FDA-approved drug Cancer Research. 70: 2773-2773. DOI: 10.1158/1538-7445.Am10-2773 |
0.327 |
|
| 2009 |
Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R. Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. The Journal of Clinical Endocrinology and Metabolism. 94: 4423-32. PMID 19820016 DOI: 10.1210/Jc.2009-0743 |
0.328 |
|
| 2009 |
Tsimberidou AM, Camacho LH, Verstovsek S, Ng C, Hong DS, Uehara CK, Gutierrez C, Daring S, Stevens J, Komarnitsky PB, Schwartz B, Kurzrock R. A phase I clinical trial of darinaparsin in patients with refractory solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4769-76. PMID 19584162 DOI: 10.1158/1078-0432.Ccr-08-2984 |
0.306 |
|
| Show low-probability matches. |